Nacrez (Desogestrel)

Desogestrel binds to progesterone receptors in the brain, suppressing the luteinizing hormone surge and thereby preventing ovulation. It also makes cervical mucus thicker, reducing sperm penetration, and changes the endometrial lining to make implantation unlikely.

The specific dosing regimen for Nacrez is determined by the prescribing healthcare professional based on individual patient factors and local guidelines. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Nacrez is contraindicated in known or suspected pregnancy because it is intended to prevent conception. Its safety during breastfeeding has not been fully established; women should discuss alternatives with their healthcare provider if they are nursing.

To request Nacrez, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nacrez (desogestrel) is a third‑generation progestogen, offering a lower risk of androgenic side effects compared with some older progestins. It provides effective contraception with a once‑daily dosing schedule, similar to other combined or progestogen‑only pills, but individual tolerance and risk profiles may differ.

Nacrez tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Nacrez is taken orally, usually once daily at the same time each day. The tablet should be swallowed whole with water and not chewed or broken. Consistency in timing helps maintain contraceptive effectiveness.

Serious risks include venous or arterial thromboembolism, severe allergic reactions, liver dysfunction, and hypertension. Women with a history of clotting disorders, smoking over age 35, or certain medical conditions should be evaluated carefully before use.

Nacrez should not be used by women who are pregnant, have active thromboembolic disease, severe liver disease, hormone‑dependent cancers, or who are known to be hypersensitive to desogestrel or any tablet excipients. Consultation with a healthcare professional is essential before starting therapy.